Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Carfilzomib, Daratumumab, Dexamethasone, Pomalidomide, Bortezomib; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 6
States / cities: Atlanta, Georgia • New York, New York • Stony Brook, New York + 3 more

Conditions: Asthma, Asthma Attack, Asthma Exacerbations
Interventions: Inhaled corticosteroid (ICS), Azithromycin, Asthma Symptom Monitoring Web-based Application; Drug · Other
Lead sponsor: DARTNet Institute; Government
Eligibility: 13 Years to 75 Years
Enrollment: 3,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 13
States / cities: Aurora, Colorado • Orlando, Florida • Kansas City, Kansas + 9 more

Conditions: Thalassemia, Hypertension, Pulmonary
Interventions: Sildenafil; Drug
Lead sponsor: Carelon Research; Other
Eligibility: 7 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Oakland, California

Conditions: Squamous NSCLC
Interventions: CV09070101 mRNA vaccine (CVHNLC) 50 µg, CV09070101 mRNA vaccine (CVHNLC) 100 µg, CV09070101 mRNA vaccine (CVHNLC) 200 µg, CV09070101 mRNA vaccine (CVHNLC) 400 µg; Biological
Lead sponsor: CureVac; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 2
States / cities: Fairfax, Virginia • Richmond, Virginia

Conditions: Inclusion Body Myositis
Interventions: Adipose Derived Regenerative Cells; Device
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Opioid-use Disorder, Amphetamine Use Disorders
Interventions: Neurocognitive Empowerment for Addiction Treatment (NEAT), Active Control; Behavioral
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Eating Behavior
Interventions: Simultaneous Variety, Single-Food, Small Portion, Large Portion; Other
Lead sponsor: Penn State University; Other
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Aggression
Interventions: Videos, Bumper stickers, Alcohol-related cues, Music, Roadside vegetation, Video game; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Drug Interactions
Interventions: CYP450 Cocktail and Transporter Substrates with Pacritinib, Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib, Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Learning, Humans, Consolidation, Sleep
Interventions: Associative inference, Category learning, Sleep; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 35 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Thyroid Cancer, Papillary Microcarcinoma
Interventions: Focus groups; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Parkinson Disease
Interventions: Omnidirectional stimulation, Directional stimulation; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 21
States / cities: Sacramento, California • Aurora, Colorado • Gainesville, Florida + 16 more

Conditions: Zika Virus, Zika Virus Infection, Virus Diseases, Flavivirus Infections, Flaviviral Diseases, Flaviviridae Infections, RNA Virus Infections
Interventions: VRC-ZKADNA090-00-VP, VRC-PBSPLA043-00-VP; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 15 Years to 35 Years
Enrollment: 2,428 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Miami, Florida • Edinburg, Texas • Houston, Texas

Conditions: Genital Herpes Simplex Type 2
Interventions: BNT163, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more

Conditions: Nicotine Dependence
Interventions: Sleep Advancement Counseling, General Health Information; Behavioral
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Ascites
Interventions: McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Rotator Cuff Tear Arthropathy
Interventions: Not listed
Lead sponsor: University of Utah; Other
Eligibility: 50 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Well Aging
Interventions: Mindfulness training (MT) Connect; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 60 Years to 95 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: End Stage Renal Disease
Interventions: Venography, Intravascular ultrasound (IVUS), Image processing; Diagnostic Test · Other
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cancer
Interventions: GSK2118436 75 mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 5
States / cities: Scottsdale, Arizona • Memphis, Tennessee • Nashville, Tennessee + 2 more

Conditions: Cystic Fibrosis
Interventions: AZD5634 for inhalation, AZD5634 for infusion, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more

Conditions: Impulse Control Disorder
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 21 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: VH4004280, Placebo, Midazolam; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Individualizing Treatment for Asthma in Primary Care (Full Study)

Sildenafil to Improve Exercise Capacity in People With Thalassemia and Pulmonary Hypertension

Safety and Tolerability of CVHNLC Plus Pembrolizumab in Patients With Squamous Non Small-Cell Lung Cancer (sqNSCLC)

Inclusion Body Myositis Treatment With Celution Processed Adipose Derived Regenerative Cells

Neurocognitive Empowerment for Addiction Treatment (NEAT) in Opioid Use Disorder and Amphetamine Use Disorder

Combined Effects of Simultaneous Variety and Portion Size on Meal Intake of Women

Aggressive Driving and Road Rage: A Driving Simulation Experiment.

Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects

Human Learning of New Structured Information Across Time and Sleep

Treatment Decision-Making Among Patients Diagnosed With Papillary Microcarcinoma and Their Significant Others

Clinical Evaluation of the Infinity Deep Brain Stimulation System

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Examination of Sleep, Smoking Cessation, and Cardiovascular Health

Impact of Palliative Catheter Placement on the Quality of Life of Patients With Refractory Ascites

The Effects of Platelet Rich Plasma on the Integrity of Rotator Cuff Repair

Mindfulness Training for Seniors

Intravascular Ultrasound in Patients With End-stage Renal Disease on Dialysis

A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors

To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Feasibility of Accelerated, Personalized rTMS as an Adjuvant for Impulse Control Disorders: a Pilot Study

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4004280 in Healthy Participants